Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Japan To Reimburse Zolgensma – But At Lower Price Than US
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
Latest From Pricing Debate
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
Medicare's CAR-T Payment Change Helps the Entire Regenerative Medicine Field ... A Little Bit
Alliance for Regenerative Medicine says CMS' plan to create new reimbursement category for CAR-T helps validate entire field, but it may not make it any easier for other products to navigate the payment landscape. ARM is prioritizing value-based payment legislation in its Congressional lobbying.
COVID-19 And The Future Of Rx Pricing Policy: An Interview With White House Advisor Grogan
White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.
'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.
Gilead’s Second Chance To Re-Set The Drug Price Debate
In 2014, Gilead’s launch of the “$1,000-a-pill” cure for hepatitis C triggered unprecedented political pressure around innovator drug pricing in the US. Now the company has the first effective therapy for COVID-19 – and a chance to re-set the political landscape for drug pricing once again.
Waste Management: How Amgen’s Kyprolis Packaging Change Could Produce Savings To Medicare
Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.
COVID-19 Shifts ICER Pricing Targets, Creating New Hurdles For Drug Developers
With a remdesivir analysis pushing cost-recovery models and lower thresholds for cost-effectiveness, ICER's COVID-19 pricing framework will likely result in lower pricing benchmarks for drugs than the group would have issued under its typical analysis framework. Critics say this is the opposite of what should be incentivized in an emergency.
AAM Offers Drug Manufacturing Repatriation Plan … For A Price
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.